BETAMETHASONE DIPROPIONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Betamethasone Dipropionate, and when can generic versions of Betamethasone Dipropionate launch?
Betamethasone Dipropionate is a drug marketed by Anda Repository, Fougera Pharms, Glenmark Pharms Inc, Padagis Israel, Taro, Actavis Mid Atlantic, Cosette, Perrigo New York, Pharmaderm, Teva, Zydus Pharms, Encube, Hikma, Alpharma Us Pharms, Fougera Pharms Inc, Padagis Us, Shree Hari Intl, Aurobindo Pharma Ltd, Lupin Ltd, Tasman Pharma, and Zydus Lifesciences. and is included in forty-seven NDAs.
The generic ingredient in BETAMETHASONE DIPROPIONATE is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Betamethasone Dipropionate
A generic version of BETAMETHASONE DIPROPIONATE was approved as betamethasone dipropionate by FOUGERA PHARMS on June 26th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BETAMETHASONE DIPROPIONATE?
- What are the global sales for BETAMETHASONE DIPROPIONATE?
- What is Average Wholesale Price for BETAMETHASONE DIPROPIONATE?
Summary for BETAMETHASONE DIPROPIONATE
| US Patents: | 0 |
| Applicants: | 21 |
| NDAs: | 47 |
| Finished Product Suppliers / Packagers: | 22 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Clinical Trials: | 66 |
| Patent Applications: | 4,047 |
| Drug Prices: | Drug price information for BETAMETHASONE DIPROPIONATE |
| Drug Sales Revenues: | Drug sales revenues for BETAMETHASONE DIPROPIONATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BETAMETHASONE DIPROPIONATE |
| What excipients (inactive ingredients) are in BETAMETHASONE DIPROPIONATE? | BETAMETHASONE DIPROPIONATE excipients list |
| DailyMed Link: | BETAMETHASONE DIPROPIONATE at DailyMed |
See drug prices for BETAMETHASONE DIPROPIONATE
Recent Clinical Trials for BETAMETHASONE DIPROPIONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wake Forest University Health Sciences | Phase 2/Phase 3 |
| Dermavant Sciences, Inc. | Phase 2/Phase 3 |
| Oticara Australia PTY LTD | Phase 2 |
Pharmacology for BETAMETHASONE DIPROPIONATE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for BETAMETHASONE DIPROPIONATE
Paragraph IV (Patent) Challenges for BETAMETHASONE DIPROPIONATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SERNIVO | Topical Spray | betamethasone dipropionate | 0.05% | 208079 | 1 | 2018-02-15 |
US Patents and Regulatory Information for BETAMETHASONE DIPROPIONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo New York | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | OINTMENT;TOPICAL | 072526-001 | Jan 31, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actavis Mid Atlantic | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | OINTMENT, AUGMENTED;TOPICAL | 074304-001 | Aug 31, 1995 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | OINTMENT;TOPICAL | 071477-001 | Aug 10, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
